Zhang Jinyong, Zeng Hao, Gu Jiang, Li Haibo, Zheng Lixin, Zou Quanming
National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing, 400038, China.
Laboratory of the Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Vaccines (Basel). 2020 Mar 29;8(2):153. doi: 10.3390/vaccines8020153.
In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.
2019年12月，由新型冠状病毒严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的肺炎疫情在中国及全球其他国家引发了严重的大流行。截至目前，全球近190个国家确诊病例超过46万例，造成全球2万多人死亡。目前，疫情仍在蔓延，且尚无有效的感染预防手段。疫苗被证明是预防和控制传染病最有效、最经济的手段。多个国家、公司和机构宣布了针对该病毒的疫苗研发计划及进展。虽然大多数疫苗仍在设计和准备阶段，但也有一些已进入动物有效性评估和初步临床试验阶段。本综述主要聚焦于针对SARS-CoV-2的疫苗研发领域的进展及前景。
